Huda Yahya Zoghbi

Huda Yahya Zoghbi

Top Cited Scholar 2025
Auto-generated profile, based on publicly available information

Huda Yahya Zoghbi

Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX

Research Focus & Metrics

Academic Career Length

42Years (1985-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 1999 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
RARuthie E. Amir
Ruthie E. Amir
IVIgnatia B. Van Den Veyver
Ignatia B. Van Den Veyver
MWMimi Wan
Mimi Wan
CTCharles Q. Tran
Charles Q. Tran
UFUta Francke
Uta Francke
HZHuda Y. Zoghbi
Huda Y. Zoghbi

28 September 2005 in Nature
Verified
Journal Article
Closed access
PDF file
Jean-Francois RualJean-Francois Rual
Jean-Francois Rual
KVKavitha Venkatesan
Kavitha Venkatesan
THTong Hao
Tong Hao
THTomoko Hirozane-Kishikawa
Tomoko Hirozane-Kishikawa
ADAmélie Dricot
Amélie Dricot
MVMarc Vidal
Marc Vidal

30 May 2008 in Science
Verified
Journal Article
Closed access
PDF file
Maria ChahrourMaria Chahrour
Maria Chahrour
SJSung Yun Jung
Sung Yun Jung
CSChad Shaw
Chad Shaw
XZXiaobo Zhou
Xiaobo Zhou
SWStephen T. C. Wong
Stephen T. C. Wong
HZHuda Y. Zoghbi
Huda Y. Zoghbi
Mutations in the gene encoding the transcriptional repressor methyl-CpG binding protein 2 (MeCP2) cause the neurodevelopmental disorder Rett syndrome. Loss of function as well as increased dosage of theMECP2gene cause a host of neuropsychiatric disorders. To explore the molecular mechanism(s) underlying these disorders, we examined gene expression patterns in the hypothalamus of mice that either lack or overexpress MeCP2. In both models, MeCP2 dysfunction induced changes in the expression levels of thousands of genes, but unexpectedly the majority of genes (∼85%) appeared to be activated by MeCP2. We selected six genes and confirmed that MeCP2 binds to their promoters. Furthermore, we showed that MeCP2 associates with the transcriptional activator CREB1 at the promoter of an activated target but not a repressed target. These studies suggest that MeCP2 regulates the expression of a wide range of genes in the hypothalamus and that it can function as both an activator and a repressor of transcription.

1 July 1993 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
HOHarry T. Orr
Harry T. Orr
MCMing-Yi Chung
Ming-Yi Chung
Sandro BanfiSandro Banfi
Sandro Banfi
TKThomas J. Kwiatkowski
Thomas J. Kwiatkowski
ASAntonio Servadio
Antonio Servadio
HZHuda Y. Zoghbi
Huda Y. Zoghbi

1 January 1997 in Nature Genetics
Verified
Journal Article
Open access
PDF file
OZOlga Zhuchenko
Olga Zhuchenko
JBJennifer Bailey
Jennifer Bailey
PBPenelope Bonnen
Penelope Bonnen
TATetsuo Ashizawa
Tetsuo Ashizawa
DSDavid W. Stockton
David W. Stockton
CLCheng Chi Lee
Cheng Chi Lee
A polymorphic CAG repeat was identified in the human α1A voltage-dependent calcium channel subunit. To test the hypothesis that expansion of this CAG repeat could be the cause of an inherited progressive ataxia, we genotyped a large number of unrelated controls and ataxia patients. Eight unrelated patients with late onset ataxia had alleles with larger repeat numbers (21‐27) compared to the number of repeats (4‐16) in 475 non‐ataxia individuals. Analysis of the repeat length in families of the affected individuals revealed that the expansion segregated with the phenotype in every patient. We identified six isoforms of the human α1A calcium channel subunit. The CAG repeat is within the open reading frame and is predicted to encode glutamine in three of the isoforms. We conclude that a small polyglutamine expansion in the human α1A calcium channel is most likely the cause of a newly classified autosomal dominant spinocerebellar ataxia, SCA6.

1 July 2007 in Annual Review of Neuroscience
Verified
Journal Article
Closed access
HOHarry T. Orr
Harry T. Orr
HZHuda Y. Zoghbi
Huda Y. Zoghbi
The discovery that expansion of unstable repeats can cause a variety of neurological disorders has changed the landscape of disease-oriented research for several forms of mental retardation, Huntington disease, inherited ataxias, and muscular dystrophy. The dynamic nature of these mutations provided an explanation for the variable phenotype expressivity within a family. Beyond diagnosis and genetic counseling, the benefits from studying these disorders have been noted in both neurobiology and cell biology. Examples include insight about the role of translational control in synaptic plasticity, the role of RNA processing in the integrity of muscle and neuronal function, the importance of Fe-S-containing enzymes for cellular energy, and the dramatic effects of altering protein conformations on neuronal function and survival. It is exciting that within a span of 15 years, pathogenesis studies of this class of disorders are beginning to reveal pathways that are potential therapeutic targets.